EUVIMEDSkopri EUVIMED
Open access

Erythrocyte patch for enhanced B cell depletion therapy

Jiaqi Liu iD, Fengju Wang iD, Lian Li iD

Science Advances · 2026-05-22 · 12 (21)

DOI: 10.1126/sciadv.aed3138 ↗

At a glance

Journal article in Science Advances, published on 2026-05-22. Written by Jiaqi Liu and 2 co-authors. Institution: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Major MEDLINE topics: Lymphocyte Depletion, B-Lymphocytes, Erythrocytes. Cited 3 times so far (Crossref); 46 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Department of Science and Technology of Sichuan Province, National key R&D program of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Dysregulated B cells are central to many hematologic malignancies and autoimmune diseases, but current B cell–targeted therapies often fail to translate binding into effective signaling. Here, we present CD20 EryPatch, a living dynamic cellular patch that co-opts natural erythrocyte processes of morphological and biological changes, enabling a dual mechanism of micrometer-scale mechanotransduction and phagocytic “tag-and-clear” for enhanced B cell depletion. CD20 EryPatches are designed to adhere to B cells and anchor on CD20 receptors across extensive cell surface areas. Their progressive discocyte-to-echinocyte transition provides deformability-driven traction, enabling localized, large-scale CD20 cross-linking that amplifies downstream apoptosis in target B cells. Concomitant biomarker alteration on CD20 EryPatch converts it into an “eat me” tag attached to the B cell, facilitating further clearance by initiating erythrophagocytosis. This approach proves more effective than standard CD20 monoclonal antibodies in models of B cell disorders, including non-Hodgkin lymphoma, systemic lupus erythematosus, and rheumatoid arthritis.

Subjects

MeSH terms (MEDLINE)

Lymphocyte DepletionB-LymphocytesErythrocytesPhagocytosisMechanotransduction, CellularAntigens, CD20ApoptosisAntibodies, MonoclonalHumansMaleAnimalsMiceCell LineMice, SCIDDisease Models, AnimalLymphoma, Non-HodgkinLupus Erythematosus, SystemicArthritis, RheumatoidMice, Inbred DBAFemale

Substances

Antigens, CD20Antibodies, Monoclonal

Authors and institutions

  • Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…

ORCID profiles: Jiaqi Liu, Fengju Wang, Lian Li

Funding

  • National Natural Science Foundation of China
  • Department of Science and Technology of Sichuan Province
  • National key R&D program of China

Cite

APA

Liu, J., Wang, F., & Li, L. (2026). Erythrocyte patch for enhanced B cell depletion therapy. Science Advances, 12(21). https://doi.org/10.1126/sciadv.aed3138

Vancouver

Liu J, Wang F, Li L. Erythrocyte patch for enhanced B cell depletion therapy. Science Advances. 2026;12(21). doi:10.1126/sciadv.aed3138

BibTeX
@article{Liu2026,
  author = {Liu, Jiaqi and Wang, Fengju and Li, Lian},
  title = {Erythrocyte patch for enhanced B cell depletion therapy},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {21},
  doi = {10.1126/sciadv.aed3138}
}
Start for free →